Tempest Therapeutics

Yahoo Finance • last month

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned to be complete in Q3 2026 to support pote... Full story

Yahoo Finance • 5 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today ann... Full story

Yahoo Finance • 5 months ago

Tempest Therapeutics announces $8.35M registered direct offering, concurrent private placement

* Tempest Therapeutics (TPST [https://seekingalpha.com/symbol/TPST]) has entered into a definitive agreement for the purchase and sale of 1.17M shares of its common stock at an offering price of $3.625 per share of common stock in a regi... Full story

Yahoo Finance • 5 months ago

Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading

(RTTNews) - Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from Novembe... Full story

Yahoo Finance • 5 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start... Full story

Yahoo Finance • 5 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today rep... Full story

Yahoo Finance • 6 months ago

Get An Even Better Deal On PMT Than Director Lynch Did

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 22, Pennymac Mortgage Investment Trust's Director, Catherine A. Lynch, invested $33,... Full story

Yahoo Finance • 8 months ago

Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.58

* Tempest Therapeutics press release [https://seekingalpha.com/pr/20196689-tempest-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:TPST [https://seekingalpha.com/symbol/TPST]): Q2 GAAP EPS of -$2.07 be... Full story

Yahoo Finance • 8 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatmen... Full story

Yahoo Finance • 10 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a... Full story

Yahoo Finance • 10 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today ann... Full story

Yahoo Finance • 11 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis... Full story

Yahoo Finance • 12 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced... Full story

Yahoo Finance • last year

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat... Full story

Yahoo Finance • last year

Tempest Reports Year End 2024 Financial Results and Provides Business Update

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into... Full story

Yahoo Finance • last year

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced... Full story

Yahoo Finance • last year

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced... Full story

Yahoo Finance • last year

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempes... Full story

Yahoo Finance • last year

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced t... Full story

Yahoo Finance • 2 years ago

11 Hot Healthcare Stocks To Buy Now

In this article, we will be taking a look at 11 hot healthcare stocks to buy now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Hot Healthcare Stocks To Buy Now. Healthcare is a vital part of dai... Full story